Time Table
Day 2, July 28 (Fri)

			7	8	9	10	11	12	13	14	15	16	17	18	19
Kobe Portopia Hotel	Room 1 (Portopia Hall)	South Building 1F		AOJ 8:20–10:20 Asia & Oceania Joint Symposium Precision medicine, its current status and possibilities for future collaborations		ISY7 10:20–12:20 Nation-wide basket/umbrella type study for precision medicine			13:30–14:20 General Assembly	Award Lecture 14:50–15:15		PS 15:30–17:00 Plenary Session	AJ 17:00–19:00 ASCO/JSMO Joint Symposium Current status of molecular targeted therapy in lung cancer		
Kobe International Exhibition Hall	Room 2 (Convention Hall South)	Hall No.2 1F		ISY8 8:20–10:20 Emerging evidence of immunocheckpoint inhibitors in non-small cell lung cancer		SL2 10:20–11:20 Evolving treatment for metastatic colorectal cancer	SL3 11:20–12:20 Training oncologists to carry out clinical trials		MeS-15 12:30–13:20 Latest Advance and Perspective in Adjuvant Chemotherapy for Resected Colon Cancer: Challenges for International Harmonization and Precision Medicine	Awards Ceremony			ISY9 17:00–19:00 The future of immune checkpoint therapy		
	Room 3 (Convention Hall North)	Hall No.2 1F		SY10 8:20–10:20 Newest knowledge in gastric cancer		ISY10 10:20–12:20 How can we manage the international gap in development of chemotherapy for gastric cancer?			MeS-16 12:30–13:20 Discussion, treatment strategy for T790M mutation positive lung cancer				SY11 17:00–19:00 Current status and perspective of the public healthcare system including non-covered services		
	Room 4 (Hall A)	Hall No.1 2F		WS8 8:50–10:20 Current landscape and future perspectives of biomarker study in breast cancer		JS2 10:20–12:20 Joint Symposium 2 (JSPM/JSMO) Changes and commentary of guidelines relating to palliative care			MeS-17 12:30–13:20 Guiding strategy of ALK positive NSCLC established in Japan				SY12 17:00–18:30 Whole Person Care ～Care for cancer patients～		
	Room 5 (Hall B)	Hall No.1 2F		SY13 8:20–10:20 Oral supportive care in cancer - promoting evidence-based clinical practices		SY14 10:20–12:20 Oral supportive care in cancer - Interprofessional Educational system to promote it			MeS-18 12:30–13:20 Future perspective of immuno checkpoint inhibitor in NSCLC				ISY11 17:00–19:00 Can preoperative therapy guide decisions on adjuvant systemic therapy?		
	Room 6 (Conference Room 2A)	Hall No.2 2F	MoS-1 7:20–8:10 Treatment of thyroid cancer by molecular target medicine	O2-1 8:40–9:40 Palliative Medicine	O2-2 9:40–10:40 Lung Cancer 1 (Chemotherapy)	WS9 10:50–12:20 Consensus and debatable issues on the treatment of poor risk germ cell tumor			MeS-19 12:30–13:20 Current topics of treatment strategies for patients with triple-negative breast cancer				O2-3 17:00–18:00 Lung Cancer 2 (Small Cell Lung Cancer / Others)	O2-4 18:00–19:00 Lung Cancer 3 (Biomarker)	
	Room 7 (Conference Room 2B)	Hall No.2 2F	MoS-2 7:20–8:10 Proteasome Inhibitors, Basic Research and Clinical Practice						MeS-20 12:30–13:20 Pathological Diagnosis and Treatment of Neuroendocrine Tumor						
	Room 8 (Conference Room 3A)	Hall No.2 3F	MoS-3 7:20–8:10 The Successful Development and Future Perspective of the Nationwide Lung Cancer Genomic Screening Project in Japan(LC-SCRUM-Japan)	SY15 8:20–10:20 Current topics in Big data, AI, genome analysis and drug discovery		SY16 10:20–12:20 To build the support system for clinical researches – "Research professionalism" supporting clinical cancer researches			MeS-21 12:30–13:20 Optimal approach to treatment of RRMM –Approaches for continuous therapy and AE management–				SY17 17:10–19:10 Role of core clinical research hospitals, correspondence to patients proposal medical treatment		
	Room 9 (Conference Room 3B)	Hall No.2 3F	MoS-4 7:20–8:10 Lung cancer related targeted therapy drugs and EGFR mutation testing –The promising plasma testing	WS10 8:20–10:20 Difference in approaches to elderly cancer patients by organs - Is it possible to unify them?		ISY12 10:20–12:20 Improving the evidence base for treating elderly patients with cancer			MeS-22 12:30–13:20 Optimal approach for patients with PD-L1+ NSCLC					18:00–19:00	
Kobe International Conference Center (ICCK)	Room 10 (Main Hall)	1F	MoS-5 7:20–8:10 2nd-line chemotherapy against metastatic Colorectal Cancer(mCRC) –efficacy and safety of ZALTRAP®, the new anti VEGF agent–	SL4 8:20–9:20 Cancer Data Collaboratives: Requirements for Personalized Medicine	EL12 9:20–9:50 Statistical aspects of clinical trials for cancer treatments	EL13 9:50–10:20 Current status of stereotactic radiation therapy(SRT)	EL14 10:20–10:50 Management of hereditary cancer syndrome in genome-based medicine	EL15 10:50–11:20 Chemotherapy for soft tissues sarcoma	EL16 11:20–11:50 Anti-caner drugs for thyroid cancer	EL17 11:50–12:20 Recent progress of molecular target therapy for breast cancer	MeS-23 12:30–13:20 The current topics and future treatment strategy in mCRC		PS 15:30–17:00 Plenary Session (relay)	EL18 17:00–17:30 Local treatment of lung cancer beyond conventional concepts	EL19 17:30–18:00 Present state and problem in COI management for clinical research in Japan	EL20 18:00–19:00 Development and validation of a multivariable prediction model: introduction of TRIPOD guideline
	Room 11 (International Conference Room)	3F	MoS-6 7:20–8:10 Management of tumor lysis syndrome (TLS)	O2-5 8:20–9:20 Immunotherapy 1	O2-6 9:20–10:20 Immunotherapy 2 (NSCLC)		O2-7 10:20–11:20 Immunotherapy 3 (Adverse Event)	Role of Medical Oncology @ Peri Operation Chemotherapy 11:20–12:20			MeS-24 12:30–13:20 What do you think ? Future treatment strategy of Luminal HER2 MBC			O2-8 17:00–18:00 Colorectal Cancer 1		O2-9 18:00–19:00 Colorectal Cancer 2
	Room 12 (Reception Hall)	3F	MoS-7 7:20–8:10 Understanding gastrointestinal tumorigenesis through cooperation of genetic alterations and microenvironment		O2-10 9:20–10:20 Endocrine Tumors / Thyroid Cancer		O2-11 10:20–11:20 Patient Advocacy / Cancer Survivorship				MeS-25 12:30–13:20 Global Strategies for the Treatment of EGFR Mutation Positive Patient			O2-12 17:00–18:00 Outpatient Chemotherapy 1		O2-13 18:00–19:00 Outpatient Chemotherapy 2
	Room 13 (501)	5F	MoS-8 7:20–8:10 Cancer treatment of CV port roles and management	WS11 8:20–10:20 Rare cancers of the head and neck area: How should we manage patients with unresectable, recurrent, or metastatic diseases?			ISY13 10:20–12:20 Treatment of carcinoma of unknown primary: Evidence-based or Science-based?				MeS-26 12:30–13:20 Prevention and management of chemotherapy-induced oral mucositis			WS12 17:00–19:00 Risk assessment in chemotherapy for the elderly cancer patients		
	Room 14 (502)	5F	MoS-9 7:20–8:10 Multi-institutional survey results leading to ideal safe handling practice	SY18 8:20–10:20 Consideration of medical care and social supports for adolescent and young adults with cancer			SY19 10:20–12:20 Usefulness of Bayesian approach in clinical trials				MeS-27 12:30–13:20 Multidisciplinary team care approach to management of skin disorders caused by molecular targeted therapies			17:00–19:00 Protection of Personal Information Session Amended act on the Protection of Personal Information in medical care and research		
	Room 15 (504+505)	5F	MoS-10 7:20–8:10 Molecular mechanism-based optimal treatment strategy for Differentiated Thyroid Cancer - Impact of TKIs on primary organs -	O2-14 8:20–9:20 Hepatoma, HCC / Biliary Tract Cancer	O2-15 9:20–10:20 Pancreatic Cancer 1		O2-16 10:20–11:20 Pancreatic Cancer 2	O2-17 11:20–12:20 Supportive Care 1 (Febrile Neutropenia / Infection)			MeS-28 12:30–13:20 Current Treatment Strategies for SCCHN			O2-18 17:00–18:00 Supportive Care 2 (Antiemetic Treatment / Others)		O2-19 18:00–19:00 Supportive Care 3 (Thrombosis / Catheter-Related Complications / Others)
	Patient Advocate Program (401+402)	4F			PAP 9:30–10:20		PAP 10:30–11:20	PAP 11:30–12:20			PAP 12:30–13:20		PAP 13:40–15:10			
Kobe International Exhibition Hall	Poster Area	Hall No.3 1F													

Explanatory Notes

- AJ =ASCO/JSMO Joint Symposium
- AOJ =ASIA & OCEANIA Joint Symposium
- PS =Plenary Session
- JS =Joint Symposium
- ISY =International Symposium
- SY =Symposium
- WS =Workshop
- EL =Educational Lecture
- SL =Special Lecture
- MoS =Morning Seminar
- MeS =Medical Seminar
- ES =Evening Seminar
- O =Oral

Simultaneous Interpretation(E&J)

E English Session

Sponsored by Princess Takamatsu Cancer Research Fund